Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 20093

Next Previous
X
Search
Drug Profile

HS 20093

Alternative Names: GSK-5764227; HS-20093

Latest Information Update: 03 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hansoh Biomedical
  • Developer GSK; Hansoh BioMedical R&D Company; Shanghai Hansoh Biomedical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase II Head and neck cancer; Oesophageal cancer; Osteosarcoma; Prostate cancer; Sarcoma; Solid tumours

Most Recent Events

  • 21 Nov 2024 Hansoh BioMedical R&D Company plans a phase I trialOsteosarcoma and Soft tissue sarcoma (Late-stage disease, Metastatic disease, Combination therapy) (IV) in December 2024 (NCT06699576)
  • 30 Sep 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Japan, Canada, Argentina, USA (IV) (NCT06551142)
  • 07 Sep 2024 Efficacy and adverse events data from phase I ARTEMIS-001 trial in Solid tumours presented at 25th World Conference on Lung Cancer (WCLC-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top